Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.

2.50
Hdl Handle:
http://hdl.handle.net/10029/7574
Title:
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
Authors:
Oostrom, A J H H M van; Plokker, H W M; Asbeck, B S van; Rabelink, T J; Kessel, K P M van; Jansen, E H J M; Stehouwer, C D A; Cabezas, M Castro
Abstract:
We investigated whether pro-inflammatory aspects of the postprandial phase can be modulated by rosuvastatin in premature coronary artery disease (CAD) patients. Herefore standardized 8 h oral fat loading tests were performed off-treatment and after rosuvastatin 40 mg/d in 20 male CAD patients (50 +/- 4 years). The expression of leukocyte activation markers CD11a, CD11b, CD62L and CD66b was studied using flowcytometry. Migration of isolated neutrophils towards chemoattractants was determined in a fluorescence-based assay. Rosuvastatin did not affect baseline leukocyte counts nor the postprandial neutrophil increment (maximum mean increase +10% pre- and +14% post-treatment, P < 0.01 for each). Rosuvastatin reduced baseline platelets (from 266 +/- 78 to 225 +/- 74 x 10(9) cells/L, P < 0.001) and blunted the postprandial platelet count change (maximum mean increase +6%, P = 0.01, and 0%, respectively). The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Pretreatment, postprandial neutrophil migration increased dose-dependently, but there were no postprandial changes after rosuvastatin. The latter effect was unrelated to changes in lipoprotein concentrations. In conclusion, in CAD patients postprandial pro-inflammatory and pro-coagulant changes can be modified by rosuvastatin. These apparently lipid-lowering independent effects may render protection against atherosclerosis.
Citation:
Atherosclerosis 2006, 185(2):331-9
Issue Date:
1-Apr-2006
URI:
http://hdl.handle.net/10029/7574
DOI:
10.1016/j.atherosclerosis.2005.06.045
PubMed ID:
16098531
Type:
Article
Language:
en
ISSN:
0021-9150
Appears in Collections:
Public Health and Health Care

Full metadata record

DC FieldValue Language
dc.contributor.authorOostrom, A J H H M van-
dc.contributor.authorPlokker, H W M-
dc.contributor.authorAsbeck, B S van-
dc.contributor.authorRabelink, T J-
dc.contributor.authorKessel, K P M van-
dc.contributor.authorJansen, E H J M-
dc.contributor.authorStehouwer, C D A-
dc.contributor.authorCabezas, M Castro-
dc.date.accessioned2007-01-17T11:00:07Z-
dc.date.available2007-01-17T11:00:07Z-
dc.date.issued2006-04-01-
dc.identifier.citationAtherosclerosis 2006, 185(2):331-9en
dc.identifier.issn0021-9150-
dc.identifier.pmid16098531-
dc.identifier.doi10.1016/j.atherosclerosis.2005.06.045-
dc.identifier.urihttp://hdl.handle.net/10029/7574-
dc.description.abstractWe investigated whether pro-inflammatory aspects of the postprandial phase can be modulated by rosuvastatin in premature coronary artery disease (CAD) patients. Herefore standardized 8 h oral fat loading tests were performed off-treatment and after rosuvastatin 40 mg/d in 20 male CAD patients (50 +/- 4 years). The expression of leukocyte activation markers CD11a, CD11b, CD62L and CD66b was studied using flowcytometry. Migration of isolated neutrophils towards chemoattractants was determined in a fluorescence-based assay. Rosuvastatin did not affect baseline leukocyte counts nor the postprandial neutrophil increment (maximum mean increase +10% pre- and +14% post-treatment, P < 0.01 for each). Rosuvastatin reduced baseline platelets (from 266 +/- 78 to 225 +/- 74 x 10(9) cells/L, P < 0.001) and blunted the postprandial platelet count change (maximum mean increase +6%, P = 0.01, and 0%, respectively). The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Pretreatment, postprandial neutrophil migration increased dose-dependently, but there were no postprandial changes after rosuvastatin. The latter effect was unrelated to changes in lipoprotein concentrations. In conclusion, in CAD patients postprandial pro-inflammatory and pro-coagulant changes can be modified by rosuvastatin. These apparently lipid-lowering independent effects may render protection against atherosclerosis.en
dc.format.extent362522 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.titleEffects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.